Opening book details…
Can I read A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants on EtoBox?
A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants by Xiaohong Wang; Na Liu; Yudong Wei; Shuang Zhang; Haiyan Li; Bei Yan; Munjal Patel; Hui Wang; Keith E. Boundy; Francheska Colon-Gonzalez; Yanqiao Zang; Xumin Zhao is a Medicine article available to read on EtoBox.
What is A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants about?
Relebactam/imipenem/cilastatin is approved in the United States to treat complicated urinary tract and intra-abdominal infections in patients who have limited or no alternative treatment options and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). Initial pharmacokinetic, safety, and tolerability studies of relebactam with and without imipenem/cilastatin included mostly Caucasian participants.
Who reads A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Xiaohong Wang; Na Liu; Yudong Wei; Shuang Zhang; Haiyan Li; Bei Yan; Munjal Patel; Hui Wang; Keith E. Boundy; Francheska Colon-Gonzalez; Yanqiao Zang; Xumin Zhao
- Publisher
- American Society for Microbiology (ISSN 0066-4804)
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)